Alembic Pharmaceuticals Limited Reports 36% Q2 Revenue Growth

Alembic Pharmaceuticals Limited reported Q2 FY27 consolidated revenue growth of 36% year-on-year to INR 2,603 crore, while profit after tax increased 81% to INR 335 crore. The quarter reflected broad-based growth across businesses, improvement in India operations, and a higher FY27 revenue growth outlook of 20% to 25%.

What did Alembic Pharmaceuticals report in Q2 FY27?

Alembic Pharmaceuticals reported consolidated revenue of INR 2,603 crore for the quarter ended September 30, 2026, up 36% year-on-year. Profit after tax rose 81% year-on-year to INR 335 crore, while management described the performance as supported by healthy contributions across its businesses.

The company also reported improved operating profitability. EBITDA increased 78% year-on-year, and EBITDA margin expanded to 22.2% from 17% in the corresponding quarter of the prior year. For the first half of FY27, consolidated revenue increased 31% year-on-year to INR 4,753 crore, while reported EBITDA grew 51% and EBITDA margin improved by 255 basis points.

How did Alembic Pharmaceuticals' India business perform?

Alembic Pharmaceuticals' India business grew 14% year-on-year in Q2 FY27, led by an 11% increase in the human health segment. This marked a return to double-digit growth for human health after the company had earlier indicated that India branded growth was below the market rate.

Management said chronic and specialty therapies are supporting the improvement. The specialty portfolio grew about 200 basis points ahead of the Indian pharmaceutical market, according to the earnings call. Animal health also remained a steady contributor, growing 23% during the quarter.

Pranav Amin, Managing Director, said commercial interventions undertaken in recent quarters were translating into better field-force productivity. Management expects improvement in the acute portfolio over the coming quarters, while retaining broadly the current scale of the field force.

What is Alembic Pharmaceuticals' FY27 outlook?

Alembic Pharmaceuticals raised its FY27 revenue growth guidance to 20% to 25% from the earlier mid-teens outlook. The company expects its U.S. generics business to grow by as much as 40% in FY27, after the segment contributed strongly to the second-quarter performance.

For India, management's stated near-term objective is to reach market-level growth within the next two to three quarters. The plan is based on sharper execution in priority brands and markets, a stronger presence in metros, and a greater contribution from chronic and specialty therapies.

The company reiterated that its India branded business is expected to grow broadly in line with the market over time and move towards double-digit growth. Its outlook for the India and ex-U.S. businesses otherwise remains unchanged, based on the commentary provided during the call.

Which businesses supported the quarter's growth?

Alembic Pharmaceuticals said the U.S. generics business was a major driver of the quarter, recording 72% year-on-year growth. The performance was aided by bosutinib outperformance and new product launches, according to the earnings call summary.

The company also announced a collaboration with DifGen Pharmaceuticals in the U.S. market. The partnership provides access to more than 20 differentiated products, with management expecting contributions from FY28 onwards. Separately, it expects the U.S. branded business to break even in the first half of FY28.

These developments indicate that the quarter's revenue growth came from more than the domestic business. India operations improved meaningfully, but management acknowledged that they still have room to catch up with the broader market. The U.S. portfolio therefore remained an important factor behind the consolidated growth rate.

What do the results mean for investors and margins?

Alembic Pharmaceuticals' higher revenue, 81% growth in profit after tax, and EBITDA margin expansion provide measurable evidence of improved profitability in Q2 FY27. Investors will also assess whether the India branded business can sustain its recovery and achieve management's target of market-level growth within two to three quarters.

Management said gross margins should remain within its guided range of 70% to 75%. It added that first-half gross margins in the high 70s were expected to continue into the second half, while full-year EBITDA margin was expected in the high teens and to move towards 20%.

The tax position is also relevant to net profitability comparisons. Alembic Pharmaceuticals moved to a normal India tax rate of 25% from FY27, while cash tax is around 18.75% because of available minimum alternate tax credit. These tax details help explain the context in which reported profit growth should be assessed.

Conclusion

Alembic Pharmaceuticals delivered a strong Q2 FY27, with consolidated revenue of INR 2,603 crore, profit after tax of INR 335 crore, and improved operating margins. Growth in U.S. generics was a major support, while the India business showed better execution through double-digit human health growth, stronger chronic and specialty therapies, and 23% growth in animal health.

The next key measure will be progress toward market-level India growth over the next two to three quarters. Investors will also watch execution against the revised FY27 revenue growth guidance of 20% to 25%, the stated high-teens EBITDA margin expectation, and the expected FY28 contribution from the DifGen Pharmaceuticals collaboration.